Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

PERFORMANCE EVALUATION OF A SARS-COV-2 RAPID ANTIGENTEST: TEST PERFORMANCE IN THE COMMUNITY IN THE NETHERLANDS

N. Van der Moeren, V.F. Zwart, E.B. Lodder, W. Van den Bijllaardt, H.R.J.M. Van Esch, J.J.J.M. Stohr, J. Pot, I. Welschen, P.M.F. Van Mechelen, S.D. Pas, J.A.J.W. Kluytmans
doi: https://doi.org/10.1101/2020.10.19.20215202
N. Van der Moeren
1Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n.vdmoeren@gmail.com
V.F. Zwart
1Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.B. Lodder
2GGD West-Brabant, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Van den Bijllaardt
3Microvida Laboratory for Medical Microbiology and Department of Infection Control, Amphia Hospital, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.R.J.M. Van Esch
1Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.J.J.M. Stohr
1Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Pot
2GGD West-Brabant, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Welschen
2GGD West-Brabant, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.M.F. Van Mechelen
2GGD West-Brabant, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.D. Pas
1Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.A.J.W. Kluytmans
4Microvida Laboratory for Medical Microbiology and Department of Infection Control, Amphia Hospital, Breda, The Netherlands and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives This study was primarily conducted to evaluate clinical sensitivity and specificity of the SARS-CoV-2 rapid antigen test ‘BD Veritor System for Rapid Detection of SARS-CoV-2’ (VRD) compared to real time reverse transcriptase polymerase chain reaction (qRT-PCR). Furthermore, the VRD sensitivity for different Ct-value groups (Ct <20; Ct 20-25, Ct 25-30 and Ct ≥30) and different intervals since symptom onset (< 7 days; ≥ 7 days) were examined.

Design Prospective performance evaluation study.

Setting Municipal Health Service (GGD) COVID-19 test centres in West-Brabant, the Netherlands

Participants In order to evaluate clinical specificity, 352 symptomatic adults (≥18 years) who presented at a participating GGD test centre for a COVID-19 test between September 28 and October 7 2020 were included. In order to evaluate clinical sensitivity, 123 symptomatic adults (≥18 years) who were tested positive with qRT-PCR in a participating GGD test centre between September 26 and October 6 were included.

Results An overall clinical specificity of 100% (95%CI: 98.9%-100%) and sensitivity of 80.7% (95% CI: 73,2%-86,9%) was found for the VRD compared to qRT-PCR. Sensitivity was the highest for low Ct-value categories and for specimen obtained within the first days after disease onset. For specimen obtained within 7 days after onset of symptoms, the overall sensitivity was 91.0% (95% CI: 82,4%-96,3%) and 98,6% (95% CI: 92,3%-100%) for samples with qRT-PCR Ct-value beneath 30.

Conclusion The VRD is a promising diagnostic test for COVID-19 community screening for symptomatic individuals within 7 days after symptom onset in function of disease control. The clinical sensitivity was highest when viral load was high, which correlated with the duration of symptoms. Further research on practical applicability and the optimal position of the test within the current testing landscape is needed.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Submitted at the Netherlands Trial Register (NTR), trial ID to be expected.

Funding Statement

Becton, Dickinson and Company was not actively involved in the design, execution, analysis or result interpretation of the study. The VRD tests for this study were provided by the Dutch Ministry of Health, Welfare and Sport (VWS). We want to thank the employees of the Microvida laboratory for Medical Microbiology at the Amphia Hospital Breda and the GGD West-Brabant for their substantial contribution to this study. Jan Kluytmans is member of the National Outbreak Management Team of The Netherlands and of a committee which supports the implementation of the Corona-reporting App.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Medical research Ethics Committees United Nieuwegein The Netherlands

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Anonimised crude data is present at the Microvida laboratory for Microbiology in Breda, The Netherlands and will be saved.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 21, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
PERFORMANCE EVALUATION OF A SARS-COV-2 RAPID ANTIGENTEST: TEST PERFORMANCE IN THE COMMUNITY IN THE NETHERLANDS
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
PERFORMANCE EVALUATION OF A SARS-COV-2 RAPID ANTIGENTEST: TEST PERFORMANCE IN THE COMMUNITY IN THE NETHERLANDS
N. Van der Moeren, V.F. Zwart, E.B. Lodder, W. Van den Bijllaardt, H.R.J.M. Van Esch, J.J.J.M. Stohr, J. Pot, I. Welschen, P.M.F. Van Mechelen, S.D. Pas, J.A.J.W. Kluytmans
medRxiv 2020.10.19.20215202; doi: https://doi.org/10.1101/2020.10.19.20215202
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
PERFORMANCE EVALUATION OF A SARS-COV-2 RAPID ANTIGENTEST: TEST PERFORMANCE IN THE COMMUNITY IN THE NETHERLANDS
N. Van der Moeren, V.F. Zwart, E.B. Lodder, W. Van den Bijllaardt, H.R.J.M. Van Esch, J.J.J.M. Stohr, J. Pot, I. Welschen, P.M.F. Van Mechelen, S.D. Pas, J.A.J.W. Kluytmans
medRxiv 2020.10.19.20215202; doi: https://doi.org/10.1101/2020.10.19.20215202

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (580)
  • Anesthesia (141)
  • Cardiovascular Medicine (1962)
  • Dentistry and Oral Medicine (253)
  • Dermatology (187)
  • Emergency Medicine (335)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (703)
  • Epidemiology (11123)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3196)
  • Geriatric Medicine (310)
  • Health Economics (567)
  • Health Informatics (2049)
  • Health Policy (864)
  • Health Systems and Quality Improvement (789)
  • Hematology (310)
  • HIV/AIDS (685)
  • Infectious Diseases (except HIV/AIDS) (12742)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (337)
  • Neurology (3004)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1561)
  • Ophthalmology (478)
  • Orthopedics (186)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (386)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2799)
  • Public and Global Health (5613)
  • Radiology and Imaging (1101)
  • Rehabilitation Medicine and Physical Therapy (637)
  • Respiratory Medicine (764)
  • Rheumatology (341)
  • Sexual and Reproductive Health (315)
  • Sports Medicine (289)
  • Surgery (348)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)